Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is -85.05% lower on its value in year-to-date trading and has touched a low of $1.58 and a high of $22.36 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMLX stock was last observed hovering at around $2.13 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $2.20, the stock is 10.93% and 15.37% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.19 million and changing 3.04% at the moment leaves the stock -72.36% off its SMA200. AMLX registered -89.11% loss for a year compared to 6-month loss of -86.15%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 8.91% gain in the last 1 month and extending the period to 3 months gives it a 20.22%, and is 11.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.05% over the week and 6.08% over the month.
Amylyx Pharmaceuticals Inc (AMLX) has around 384 employees, a market worth around $149.78M and $298.76M in sales. Profit margin for the company is -55.52%. Distance from 52-week low is 39.68% and -90.16% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.29%).
The EPS is expected to shrink by -623.81% this year, but quarterly earnings will post -77.00% year-over-year.
Amylyx Pharmaceuticals Inc (AMLX) Top Institutional Holders
169.0 institutions hold shares in Amylyx Pharmaceuticals Inc (AMLX), with institutional investors hold 92.91% of the company’s shares. The shares outstanding are 67.71M, and float is at 46.02M with Short Float at 4.03%. Institutions hold 79.71% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 5.35 million shares valued at $$15.19 million. The investor’s holdings represent 7.9332 of the AMLX Shares outstanding. As of 2024-03-31, the second largest holder is BLACKROCK INC. with 4.47 million shares valued at $$12.71 million to account for 6.6376 of the shares outstanding. The other top investors are GOLDMAN SACHS GROUP INC which holds 2.94 million shares representing 4.3658 and valued at over $$8.36 million, while MILLENNIUM MANAGEMENT LLC holds 3.666 of the shares totaling 2.47 million with a market value of $$7.02 million.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
The most recent transaction is an insider purchase by Quimi Daphne,the company’sDirector. SEC filings show that Quimi Daphne bought 2,750 shares of the company’s common stock on May 14 ’24 at a price of $1.89 per share for a total of $5184.0. Following the purchase, the insider now owns 2750.0 shares.
Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on May 15 ’24 that Quimi Daphne (Director) bought a total of 2,250 shares of the company’s common stock. The trade occurred on May 15 ’24 and was made at $1.89 per share for $4252.0. Following the transaction, the insider now directly holds 5000.0 shares of the AMLX stock.
Still, SEC filings show that on May 15 ’24, Mazzariello Gina (Chief Legal Officer) disposed off 10,455 shares at an average price of $1.88 for $19654.0. The insider now directly holds 151,477 shares of Amylyx Pharmaceuticals Inc (AMLX).
